Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial

RCT (n=2,184) found single-dose baloxavir had superior efficacy to placebo (73.2h vs. 102.3h; difference 29.1h [95% CI 14.6 to 42.8], p<0.0001) and similar efficacy to oseltamivir (81.0h; difference from baloxavir 7.7h) in time to improvement of influenza symptoms.

SPS commentary:

Baloxavir marboxil, a selective inhibitor of influenza cap-dependent endonuclease, is licensed in the US for the treatment and prophylaxis of Type A and B influenza in people aged 12 years and older. The UK and EU developmental status is unknown.


The Lancet Infectious Diseases